TapewireFind a company

person · Reporting owner

Matthews Judith M.

Disclosed activity across 2 companies

Tapewire entity
26654
SEC CIK
0001734033

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Eton Pharmaceuticals, Inc.ETON · Entity 4598Chief Financial OfficerJuly 31, 2026August 04, 2026
Iterum Therapeutics plcITRM · Entity 72802Chief Financial OfficerMarch 31, 2023April 04, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Eton Pharmaceuticals, Inc.

Report date July 31, 2026 · Filed August 04, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table II · derivative / convertible securityDirect32,246 Reported balance After 2026-07-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-07-31 · Grant · Acquired 32,246 · Balance 32,246

F1: On July 31, 2026, the reporting person was granted 32,246 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.

Filing footnotes · ownership attribution and instrument terms

F1: On July 31, 2026, the reporting person was granted 32,246 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.

Iterum Therapeutics plc

Report date March 31, 2023 · Filed April 04, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2033-03-30Direct100,000 Reported balance After 2023-03-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-03-31 · Grant · Acquired 100,000 · Balance 100,000

F1: The shares underlying this option shall vest at a rate of 33.3% of the total number of shares on the one-year anniversary of March 31, 2023 and the remaining 66.7% will vest in equal monthly installments thereafter until March 31, 2026, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest at a rate of 33.3% of the total number of shares on the one-year anniversary of March 31, 2023 and the remaining 66.7% will vest in equal monthly installments thereafter until March 31, 2026, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 31, 2026 Filed Aug 4, 2026 21:04 UTC Eton Pharmaceuticals, Inc. ETON · Entity 4598 GrantCommon Stock · Derivative 32,246 $0.00 $0.00
Disclosure

SEC source: 0001437749-26-025715 · rdgdoc.xml · derivative · entry 1

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,246

Underlying: Common Stock · 32,246 shares

Expires not disclosed

F1 · derivative.exercise_price: On July 31, 2026, the reporting person was granted 32,246 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.

F1 · derivative.exercise_date: On July 31, 2026, the reporting person was granted 32,246 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.

F1 · derivative.expiration_date: On July 31, 2026, the reporting person was granted 32,246 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 00:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantStock Option (Right to Buy) · Derivative 100,000 $0.00 Strike: $1.00 $0.00
Disclosure

SEC source: 0001209191-23-022423 · doc4.xml · derivative · entry 1

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Ordinary Shares · 100,000 shares

Expires 2033-03-30

F1 · derivative.exercise_date: The shares underlying this option shall vest at a rate of 33.3% of the total number of shares on the one-year anniversary of March 31, 2023 and the remaining 66.7% will vest in equal monthly installments thereafter until March 31, 2026, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date.

Read SEC document
March 11, 2023 Filed Mar 14, 2023 22:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionRestricted Share Units · Derivative 6,666 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-018585 · doc4.xml · derivative · entry 3

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 6,666 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

F4 · derivative.exercise_date: On March 11, 2021, the reporting person was granted an award of 13,333 RSUs, 50% of which vested on March 11, 2022, with the remaining 50% having vested on March 11, 2023.

F4 · derivative.expiration_date: On March 11, 2021, the reporting person was granted an award of 13,333 RSUs, 50% of which vested on March 11, 2022, with the remaining 50% having vested on March 11, 2023.

F2 · derivative.underlying_shares: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split.

Read SEC document
March 11, 2023 Filed Mar 14, 2023 22:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Tax withholdingOrdinary Shares 2,883 $0.96 $2,767.68
Disclosure

SEC source: 0001209191-23-018585 · doc4.xml · nonDerivative · entry 2

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,135

F3 · shares: Represents the ordinary shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted RSUs.

Read SEC document
March 11, 2023 Filed Mar 14, 2023 22:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantOrdinary Shares 6,666 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-018585 · doc4.xml · nonDerivative · entry 1

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,018

F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

F2 · balance_after: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split.

Read SEC document
March 14, 2022 Filed Mar 15, 2022 23:12 UTC Amendment Iterum Therapeutics plc ITRM · Entity 72802 SaleOrdinary Shares 63,340 $0.31 $19,635.40
Disclosure

SEC source: 0001209191-22-018976 · doc4a.xml · nonDerivative · entry 1

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,292

F1 · shares: Represents the ordinary shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of restricted share units. This amendment is being filed to address an error in reporting the number of ordinary shares sold pursuant to such election and the sale price per share. This sale does not represent a discretionary trade by the reporting person.

F2 · price: Restricted share units converted into ordinary shares on a one-for-one basis upon vesting of the restricted share units. This amendment is being filed to address an error in reporting the number of ordinary shares sold pursuant to such election and the sale price per share. This sale does not represent a discretionary trade by the reporting person.

Read SEC document
March 14, 2022 Filed Mar 15, 2022 21:01 UTC Iterum Therapeutics plc ITRM · Entity 72802 SaleOrdinary Shares 47,132 $0.38 $17,910.16
Disclosure

SEC source: 0001209191-22-018864 · doc4.xml · nonDerivative · entry 2

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,500

F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the RSUs. This sale does not represent a discretionary trade by the reporting person.

Read SEC document
March 11, 2022 Filed Mar 15, 2022 21:01 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionRestricted Share Units · Derivative 100,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-018864 · doc4.xml · derivative · entry 3

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Ordinary Shares · 100,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

F3 · derivative.exercise_date: On March 11, 2021, the reporting person was granted an award of 200,000 RSUs, 50% of which vested on March 11, 2022.

F3 · derivative.expiration_date: On March 11, 2021, the reporting person was granted an award of 200,000 RSUs, 50% of which vested on March 11, 2022.

Read SEC document
March 11, 2022 Filed Mar 15, 2022 21:01 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantOrdinary Shares 100,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-018864 · doc4.xml · nonDerivative · entry 1

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,632

F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

Read SEC document
June 23, 2021 Filed Jun 25, 2021 20:05 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantStock Option (Right to Buy) · Derivative 1,936,000 $0.00 Strike: $2.01 $0.00
Disclosure

SEC source: 0000899243-21-025951 · doc4.xml · derivative · entry 1

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,936,000

Underlying: Ordinary Shares · 1,936,000 shares

Expires 2031-06-22

F1 · derivative.exercise_date: The shares underlying this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of June 23, 2021 and the remaining 75% will vest in equal monthly installments thereafter until June 23, 2025, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date.

Read SEC document
March 11, 2021 Filed Mar 15, 2021 20:30 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantRestricted Share Units · Derivative 200,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-011584 · doc4.xml · derivative · entry 1

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Ordinary Shares · 200,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU.

F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer on the relevant vesting date and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, the RSUs shall vest 50% on March 11, 2022 and 50% on March 11, 2023.

F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer on the relevant vesting date and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, the RSUs shall vest 50% on March 11, 2022 and 50% on March 11, 2023.

Read SEC document
January 26, 2021 Filed Jan 28, 2021 00:32 UTC Iterum Therapeutics plc ITRM · Entity 72802 SaleOrdinary Shares 33,868 $1.73 $58,591.64
Disclosure

SEC source: 0000899243-21-003518 · doc4.xml · nonDerivative · entry 2

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,632

F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the PSUs. This sale does not represent a discretionary trade by the reporting person.

Read SEC document
January 25, 2021 Filed Jan 28, 2021 00:32 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantOrdinary Shares 62,500 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-003518 · doc4.xml · nonDerivative · entry 1

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,500

F1 · shares: Consists of 62,500 ordinary shares received upon vesting of performance-based stock units ("PSUs") on January 25, 2021, which PSUs were subject to performance conditions that have been satisfied. PSUs convert into ordinary shares on a one-for-one basis.

Read SEC document
September 30, 2020 Filed Oct 3, 2020 01:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 SaleOrdinary Shares 56,130 $1.64 $92,053.20
Disclosure

SEC source: 0000899243-20-027008 · doc4.xml · nonDerivative · entry 1

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020.

Read SEC document
February 15, 2019 Filed Feb 19, 2019 16:29 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $5.80 $0.00
Disclosure

SEC source: 0000899243-19-003970 · doc4.xml · derivative · entry 1

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Ordinary Shares · 30,000 shares

Expires 2029-02-14

F1 · derivative.exercise_date: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of February 15, 2019 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date.

Read SEC document
May 30, 2018 Filed May 30, 2018 21:12 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionSeries B-2 Preferred Shares · Derivative 2,466 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-034193 · doc4.xml · derivative · entry 7

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 2,466 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F3 · derivative.exercise_date: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4 · derivative.expiration_date: Not applicable.

Read SEC document
May 30, 2018 Filed May 30, 2018 21:12 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionSeries B-1 Preferred Shares · Derivative 3,038 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-034193 · doc4.xml · derivative · entry 6

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,038 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F2 · derivative.exercise_date: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4 · derivative.expiration_date: Not applicable.

Read SEC document
May 30, 2018 Filed May 30, 2018 21:12 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionSeries A Preferred Shares · Derivative 10,980 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-034193 · doc4.xml · derivative · entry 5

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 10,980 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F1 · derivative.exercise_date: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4 · derivative.expiration_date: Not applicable.

Read SEC document
May 30, 2018 Filed May 30, 2018 21:12 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseOrdinary Shares 4,000 $13.00 $52,000.00
Disclosure

SEC source: 0001209191-18-034193 · doc4.xml · nonDerivative · entry 4

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,130

Read SEC document
May 30, 2018 Filed May 30, 2018 21:12 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionOrdinary Shares 2,466 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-034193 · doc4.xml · nonDerivative · entry 3

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,130

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

Read SEC document
May 30, 2018 Filed May 30, 2018 21:12 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionOrdinary Shares 3,038 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-034193 · doc4.xml · nonDerivative · entry 2

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,664

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

Read SEC document
May 30, 2018 Filed May 30, 2018 21:12 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionOrdinary Shares 10,980 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-034193 · doc4.xml · nonDerivative · entry 1

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,626

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

Read SEC document
May 24, 2018 Filed May 29, 2018 21:13 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantStock Option (Right to Buy) · Derivative 23,870 $0.00 Strike: $13.00 $0.00
Disclosure

SEC source: 0001209191-18-033895 · doc4.xml · derivative · entry 1

Matthews Judith M. · CIK 0001734033 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,870

Underlying: Ordinary Shares · 23,870 shares

Expires 2028-05-23

F1 · derivative.exercise_date: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of May 24, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.